June 23, 2018
Investigators defined control of parameters by systolic BP
ORLANDO – In patients with type 2 diabetes (T2D) and cardiovascular disease, empagliflozin reduces the risk for incident or worsening nephropathy regardless of whether blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), or hemoglobin (Hb)A1c are controlled, according to results presented at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Florida, June 22-26, 2018.
The study included participants with T2D and established cardiovascular disease (n=6185). Participants were randomly assigned to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. The researchers assessed the risk for incident or worsening nephropathy, controlling for BP, LDL-C, and HbA1c. They defined control of systolic BP as <140 mm Hg, diastolic BP as <90 mm Hg, LDL-C as <100 mg/dL, and HbA1c as <7.5%.
When the researchers adjusted for control of BP, the hazard ratio (HR) for time to incident or worsening nephropathy with empagliflozin vs placebo was 0.67 (95% CI, 0.59-0.76). When they adjusted for control of LDL-C, the HR was 0.61 (95% CI, 0.53-0.69), and when they adjusted for control of HbA1c, it was 0.65 (95% CI, 0.57-0.74).